Plain-English translation of NCT06318169 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This clinical trial is testing a medication called to see if it can help treat liver fibrosis (scarring) in people with metabolic dysfunction-associated steatohepatitis, commonly called MASH or fatty liver disease. Researchers want to understand whether this medication works better than a placebo (inactive pill) and whether it is safe for patients to use. The study will enroll about 1,350 people and test two different doses of the medication.
Fatty liver disease with scarring can lead to serious liver damage if left untreated, and currently there are limited treatment options available. This study aims to find out whether this medication could offer patients a new way to slow down or even reverse liver scarring.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the new medication, a second dose of the medication, or a placebo pill. You will take your assigned treatment on a regular schedule and visit the study clinic for check-ups and blood tests to monitor your liver health and watch for any side effects. The study will follow you over time to see whether the medication helps slow or stop liver scarring compared to placebo.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States